Characterization of the Inflammatory Phenotype in Atherosclerosis May Contribute to the Development of New Therapeutic and Preventative Interventions

Trends in Cardiovascular Medicine

Volumn 20, Issue 5, 2010, Pages 176-181

  Puntmann, Valentina O ^a   Bigalke, Boris ^a,b   Nagel, Eike ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT; NEW DRUG;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC INFLAMMATION; HUMAN; INFLAMMATORY DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; THROMBOCYTE ACTIVATION;

ATHEROSCLEROSIS; HUMANS; INFLAMMATION; PHENOTYPE;

EID: 79960092330     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2011.03.001     Document Type: Review

References (39)

1. Abd T.T., Eapen D.J., Bajpai A., et al. The role of C-reactive protein as a risk predictor of coronary atherosclerosis: Implications from the JUPITER trial. Curr Atheroscler Rep 2011, 13:154-161.
2. Bhagat K., Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation 1997, 96:3042-3047.
3. Bigalke B., Lindemann S., Ehlers R., et al. Expression of platelet collagen receptor glycoprotein VI is associated with acute coronary syndrome. Eur Heart J 2006, 27:2165-2169.
4. Bonetti P.O., Lerman L.O., Lerman A. Endothelial dysfunction: A marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003, 23:168-175.
5. Choi H.K., Hernan M.A., Seeger J.D., et al. Methotrexate and mortality in patients with rheumatoid arthritis: A prospective study. Lancet 2002, 359:1173-1177.
6. Davies J.E., Parker K.H., Francis D.P., et al. What is the role of the aorta in directing coronary blood flow?. Heart 2008, 94:1545-1547.
7. Everett B.M., Glynn R.J., MacFadyen J.G., Ridker P.M. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER). Circulation 2010, 12:143-150.
8. Feldman A.M., Li Y.Y., McTiernan C.F. Matrix metalloproteinases in pathophysiology and treatment of heart failure. Lancet 2001, 357:654-655.
9. Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res 2004, 61:498-511.
10. Golman K., Petersson J.S., Magnusson P., et al. Cardiac metabolism measured noninvasively by hyperpolarized 13C MRI. Magn Reson Med 2008, 59:1005-1013.
11. Gonzalez A., Maradit Kremers H., Crowson C.S., et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?. Ann Rheum Dis 2008, 67:64-69.
12. Gonzalez-Gay M.A., De Matias J.M., Gonzalez-Juanatey C., et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006, 24:83-86.
13. Gonzalez-Gay M.A., Gonzalez-Juanatey C., Martin J. The increased risk of ventricular diastolic dysfunction and congestive heart failure in patients with rheumatoid arthritis is independent of the duration of the disease. Semin Arthritis Rheum 2005, 35:132-133.
14. Graham I., Borch-Johnsen K., Boysen G., et al. European guidelines on cardiovascular disease prevention in clinical practice: Executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2007, 28:2375-2414.
15. Hällgren R., Berne C. Glucose intolerance in patients with chronic inflammatory diseases is normalized by glucocorticoids. Acta Med Scand 1983, 213:351-355.
16. Hamid T., Gu Y., Ortines R.V., et al. Divergent tumor necrosis factor receptor-related remodeling responses in heart failure: Role of nuclear factor-kappaB and inflammatory activation. Circulation 2009, 119:1386-1397.
17. Heeschen C., Dimmeler S., Hamm C.W., et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003, 348:1104-1111.
18. Higuchi Y., McTiernan C.F., Frye C.B., et al. Tumor necrosis factor receptors 1 and 2 differentially regulate survival, cardiac dysfunction, and remodeling in transgenic mice with tumor necrosis factor-alpha-induced cardiomyopathy. Circulation 2004, 109:1892-1897.
19. Kahn R., Robertson R.M., Smith R., Eddy D. The impact of prevention on reducing the burden of cardiovascular disease. Circulation 2008, 118:576-585.
20. Kim W.Y., Astrup A.S., Stuber M., et al. Subclinical coronary and aortic atherosclerosis detected by magnetic resonance imaging in type 1 diabetes with and without diabetic nephropathy. Circulation 2007, 115:228-235.
21. Leichman J.G., Lavis V.R., Aguilar D., et al. The metabolic syndrome and the heart-A considered opinion. Clin Res Cardiol 2006, 95:i134-i141.
22. Mäki-Petäjä K.M., Booth A.D., Hall F.C., et al. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol 2007, 50:852-858.
23. Mann D.L. Inflammatory mediators and the failing heart: Past, present and foreseeable future. Circ Res 2002, 91:988-998.
24. McCarey D., McInnes I., Madhok R., et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): Double-blind, randomised placebo-controlled trial. Lancet 2004, 363:2015-2021.
25. Müller K., Aichele S., Herkommer M., et al. Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease. Atherosclerosis 2010, 213:256-262.
26. Neubauer S. The failing heart-An engine out of fuel. N Eng J Med 2007, 356:1140-1151.
27. Niederer S.A., Fink M., Noble D., Smith N.P. A meta-analysis of cardiac electrophysiology computational models. Exp Physiol 2009, 94(5):486-495.
28. Perseghin G., Ntali G., De Cobelli F., et al. Abnormal left ventricular energy metabolism in obese men with preserved systolic and diastolic functions is associated with insulin resistance. Diabetes Care 2007, 30:1520-1536.
29. Puntmann V.O., Mayr M. Phenotyping transgenic animals-An integrated readout of pathophysiology by combining proteomics and metabolomics with cardiovascular imaging. J Mol Cell Cardiol 2010, 48:571-573.
30. Puntmann V.O., Taylor P.C., Barr A., et al. Towards understanding the phenotypes of myocardial involvement in the presence of self-limiting and sustained systemic inflammation: A magnetic resonance imaging study. Rheumatology (Oxford) 2010, 49(3):528-535.
31. Puntmann V.O., Taylor P.C., Mayr M. Coupling vascular and myocardial inflammatory injury into a common phenotype of cardiovascular dysfunction: Systemic inflammation and aging-A mini-review. Gerontology 2010, June 11, [Epub ahead of print].
32. Schoenhagen P., Nagel E. Noninvasive assessment of coronary artery disease anatomy, physiology, and clinical outcome. JACC Cardiovasc Imaging 2011, 4:62-64.
33. Schoenhagen P., White R.D., Nissen S.E., Tuzcu E.M. Coronary imaging: Angiography shows the stenosis, but IVUS, CT, and MRI show the plaque. Cleve Clin J Med 2003, 70:713-719.
34. Szmitko P.E., Wang C.H., Weisel R.D., et al. New markers of inflammation and endothelial cell activation: Part I. Circulation 2003, 108:1917-1923.
35. Taegtmeyer H., Golfman L., Sharma S., et al. Linking gene expression to function: Metabolic flexibility in the normal and diseased heart. Ann N Y Acad Sci 2004, 1015:202-213.
36. Taylor P.C., Feldmann M. Anti-TNF biologic agents: Still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol 2009, 5:578-582.
37. Taylor P.C., Sivakumar B. Hypoxia and angiogenesis in rheumatoid arthritis. Curr Opin Rheumatol 2005, 17:293-298.
38. Van den Borne S.W., Diez J., Blankesteijn W.M., et al. Myocardial remodeling after infarction: the role of myofibroblasts. Nat Rev Cardiol 2010, 7:30-37.
39. van Leuven S.I., Kastelein J.J., D'Cruz D.P., et al. Atherogenesis in rheumatology. Lupus 2006, 15:117-121.